President Marco Tinelli Scientific Committee Marco Tinelli Mario Venditti Ercole Concia Annalisa Pantosti Massimo Galli

Similar documents
Marco Tinelli. Giampiero Carosi

Mestre-Venice, October 25 th -26 th NH Laguna Palace Hotel Mestre, Venice

Course Coordinators. Course Objectives. Target Audience

Healthcare Facilities and Healthcare Professionals. Public

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

Summary of the latest data on antibiotic resistance in the European Union

Antimicrobial Stewardship: The South African Perspective

UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM

Impact of Antimicrobial Stewardship Program

Antimicrobial Stewardship

Antimicrobial Stewardship: efective implementation for improved clinical outcomes

Antibiotic Resistance in the Post-Acute and Long-Term Care Settings: Strategies for Stewardship

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011

EVIDENCE BASED MEDICINE: ANTIBIOTIC RESISTANCE IN THE ELDERLY CHETHANA KAMATH GERIATRIC MEDICINE WEEK

2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea

Geriatric Mental Health Partnership

Prevention and control of antimicrobial resistance in healthcare settings: raising awareness about best practices

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs

Antimicrobial Stewardship:

Antimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS

Antimicrobial Resistance Initiative

MHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative

Antibiotic Stewardship in Nursing Homes SAM GUREVITZ PHARM D, CGP ASSOCIATE PROFESSOR BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCE

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY REFERENCES: MALTA, COUNTRY VISIT AMR. STOCKHOLM: ECDC; DG(SANTE)/

ANTIBIOTIC STEWARDSHIP

POTENTIAL STRUCTURE INDICATORS FOR EVALUATING ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN EUROPEAN HOSPITALS

MDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC

Antimicrobial stewardship as a tool to fight resistance

AALAS affiliate BETTER EDUCATION FOR BETTER SCIENCE

Clinical Guideline. District Infectious Diseases Management. Go to Guideline. District Infectious Diseases Management CG 18_24

Implementing Antibiotic Stewardship in Rural and Critical Access Hospitals

11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose

8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM

Dr Eleri Davies. Consultant Microbiologist and Infection Control Doctor, Public Health Wales NHS Trust

LINEE GUIDA: VALORI E LIMITI

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection

LEGAL SEMINAR on Legal Issues in Receivables Finance

7th International Course in PEDIATRIC AIRWAY: LIVE SURGERY, LECTURES, ALBATROSS CASES

Multi-Drug Resistant Organisms (MDRO)

Antimicrobial stewardship

Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources

Best Practices for Antimicrobial Stewardship Programs. October 25, :00 AM 5:00 PM New Orleans, LA Room:

Community-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antimicrobial Stewardship in the Hospital Setting

Antibiotic Stewardship Beyond Hospital Walls

12 th Biennial STVM Conference 2014

Antibiotic resistance: the rise of the superbugs

Advances in Antimicrobial Stewardship (AMS) at University Hospital Southampton

How is Ireland performing on antibiotic prescribing?

Antibiotic Stewardship and Critical Access Hospitals. Robert White, BA, PT, CPHQ Program Manager TMF Quality Innovation Network

INTERNATIONAL SYMPOSIUM ON ANTIMICROBIAL RESISTANCE

The South African AMR strategy. 3 rd Annual Regulatory Workshop Gavin Steel Sector wide Procurement National Department of Health; South Africa

Promoting Appropriate Antimicrobial Prescribing in Secondary Care

Antimicrobial Stewardship Esperienza Torinese

Physician Veterinarian Do you have the Bayer Spirit?

Commonwealth of Kentucky Antibiotic Stewardship Practice Assessment For Long-Term Care Facilities

OBJECTIVES. Fast Facts 3/23/2017. Antibiotic Stewardship Beyond Hospital Walls. Antibiotics are a shared resource and becoming a scarce resource.

Physician Rating: ( 23 Votes ) Rate This Article:

The Nuts and Bolts of Antibiograms in Long-Term Care Facilities

Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Keeping Antibiotics Working: Nursing Leadership in Action

2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

Summary of the latest data on antibiotic consumption in the European Union

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS

National Action Plan development support tools

7th International Course in PEDIATRIC AIRWAY: LIVE SURGERY, LECTURES, ALBATROSS CASES

Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?

Resolution adopted by the General Assembly on 5 October [without reference to a Main Committee (A/71/L.2)]

Surveillance of AMR in PHE: a multidisciplinary,

ASCENSION TEXAS Antimicrobial Stewardship: Practical Implementation Strategies

ANTIMICROBIAL STEWARDSHIP IN PRIMARY HEALTH CARE WESTERN CAPE GOVERNMENT: HEALTH METRO DISTRICT FINDINGS 6 MONTHS AFTER INITIATION

AMR epidemiological situation: ECDC update

Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S.

Antimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services

NUOVE IPOTESI e MODELLI di STEWARDSHIP

Testimony of the Natural Resources Defense Council on Senate Bill 785

Updates in Antimicrobial Stewardship

Presenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update

What is an Antibiotic Stewardship Program?

Preventing and Responding to Antibiotic Resistant Infections in New Hampshire

WHO Surgical Site Infection Prevention Guidelines. Web Appendix 4

What is the problem? Latest data on antibiotic resistance

Hospital Acquired Infections in the Era of Antimicrobial Resistance

Collecting and Interpreting Stewardship Data: Breakout Session

Bugs, Drugs, and No More Shoulder Shrugs: The Role for Antimicrobial Stewardship in Long-term Care

Ready to Launch: Antimicrobial Stewardship for All!

Mike Apley Kansas State University

Implementation and Optimization of Antibiotic Stewardship in Acute Care Hospitals: A Clinical Microbiology Laboratory Perspective

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal

The Infected Implant in Orthopaedic Reconstruction: An Update on the Clinical and Molecular Approaches to Prevention and Diagnosis

Antimicrobial Stewardship

Understanding the Hospital Antibiogram

Council Conclusions on Antimicrobial Resistance (AMR) 2876th EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS Council meeting

CALL FOR ABSTRACT. Under the Patronage of H. H. Sheikh Nahayan Mabarak Al Nahayan Minister of Education and Chancellor of the UAE University

The Rise of Antibiotic Resistance: Is It Too Late?

ECDC activities on antimicrobial resistance & healthcare-associated infections (ARHAI Programme) Ülla-Karin Nurm, ECDC Tallinn, 13 May 2013

Transcription:

President Marco Tinelli Scientific Committee Marco Tinelli Mario Venditti Ercole Concia Annalisa Pantosti Massimo Galli Organizing Secretariat Nadirex International Via Riviera, 39 27100 Pavia (Italy) Tel. +39 0382 525735/14 Fax +39 0382 525736 E-mail: info@nadirex.com www.nadirex.com CME Provider Nº 265 Nadirex International Via Riviera, 39 27100 Pavia (Italy) Tel. +39 0382 525735/14 Fax +39 0382 525736 E-mail: info@nadirex.com www.nadirex.com 2

The sixth edition of AMIT Congress continues in the tradition to propose topics of great interest and current importance in Infectious Diseases. Following the philosophy of the Congress, topics are presented to the participants by the international leading specialists. Precision medicine, microbiota and genotypical microbiological diagnostic will be focused in the opening session to better understand their impact in infectious diseases now and in the future. An update of new HAART options, the HIV/HCV co-infections and new antiviral drugs in viral hepatitis, of great importance for the clinician, will be discussed in a specific session. In Italy, one of the main problems in the epidemiology of infectious diseases is the achievement of data about multidrug-resistant microorganisms. The variability of the different health care settings: hospitals, long-term care facilities, long-term acute care facilities, ambulatory surgical centers, dialysis centers and private practices does not always allow enough available data for a statistical analysis to be obtained. Rational and effective models of infection control to face the spreading of the multidrug-resistant microorganisms in different health care settings will be discussed during the Congress. In a scenario of widespreading resistant microrganisms with little or no sensitivity to antibiotics, the treatment optimization is a challenge of prime importance for the clinician. Antimicrobial stewardship is the cornerstone for tackling antimicrobial resistance. This, in order to coordinate interventions designed to improve and measure the appropriate use of antimicrobials by promoting the selection of the optimal antimicrobial drug regimen, dose, duration of therapy, and route of administration. Coordinated legislative or regulatory mandates designed to optimize the use of antimicrobial therapy through antimicrobial stewardship programmes started recently in Italy. The role and the involvement of the Infectious Disease Specialist will be increasingly addressed to the transition of care from the acute care settings, where rates of admission are reduced, to the outpatient settings. The Infectious Disease consultation services improve quality-of-care, patient outcomes and antibiotic treatment strategies. This involvement of the Infectious Disease Specialist is essential for improving the healthcare system. Presentation Marco Tinelli 3

4Faculty Massimo Andreoni Division of Infectious Diseases, Tor Vergata University Hospital, Rome Matteo Bassetti Division of Infectious Diseases, University Hospital of Udine, Udine Robert Bonomo Medical Service, Louis Stokes Cleveland Department of Veteran Affairs Medical Center, Department of Medicine, University Hospitals Cleveland Medical Center Silvio Borrè Division of Infectious Diseases, ASL Vercelli, Vercelli Bruno Cacopardo Division of Infectious Diseases, Garibaldi Hospital, University of Catania, Catania Thierry Calandra Department of Medicine, Infectious Diseases Unit, University Hospital Vaudois, Lausanne, Switzerland Antonio Cascio Division of Infectious Diseases and AIDS Regional Center, P. Giaccone Hospital, University of Palermo, Palermo Francesco Castelli Division of Infectious Diseases, University Hospital of Brescia Dario Cattaneo Unit of Clinical Pharmacology, Fatebenefratelli and Sacco Hospitals, University of Milan Antonio Chirianni Division of Infectious Diseases, "Monaldi-Cotugno-CTO" Hospital, Naples Ercole Concia Division of Infectious Diseases, University Hospital of Verona, Verona Carlo Contini Institute of Infectious Diseases, University of Ferrara, Ferrara Paul Cotter Teagasc Food Research Center, Moorepark,APC Institute, Cork Institute of Technology, Cork, Ireland Antonella d Arminio Monforte Department of Medicine, Surgery and Dentistry, Division of Infectious Diseases, Santi Paolo and Carlo Hospitals, University of Milan, Milan Antonio Davì Division of Infectious Diseases, Hospital of Modica, Modica Andrea Endimiani Institute of Infectious Diseases, University of Bern, Bern, Switzerland Silvano Esposito Department of Medicine, Surgery and Dentistry, Salerno Medical School, Salerno Marco Falcone Division of Public Health and Infectious Diseases, La Sapienza University, Rome Antonina Franco Division of Infectious Diseases, Umberto I Hospital, Siracusa Fabio Franzetti Division of Infectious and Tropical Diseases, Fatebenefratelli Sacco Hospital, Milan Giovanni Battista Gaeta Division of Infectious Diseases, University Hospital of Naples, Naples Massimo Galli Division of Infectious Diseases, Fatebenefratelli and Sacco Hospitals, University of Milan, Milan Gaetan Gavazzi Division of Infectious Diseases, University of Grenoble, Grenoble Tommaso Giani Department of Medical Biotechnologies, University of Siena, Department of Experimental and Clinical Medicine, University of Florence; Clinical Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy

Paolo Grossi Division of Infectious Diseases, Macchi Foundation, Hospital of Varese, University of Insubria, Varese Carmelo Iacobello Division of Infectious Diseases, Cannizzaro Hospital, Catania Stefania Iannazzo Department of Health Prevention, Ministry of Health, Rome Ed Kujiper Department of Experimental Microbiology, Leiden University Medical Center, Leiden, Netherlands Francesco Luzzaro Laboratory of Microbiology, Hospital of Lecco, Lecco Giacomo Magnani Division of Infectious Diseases, Arcispedale Santa Maria Nuova Hospital, Reggio Emilia Francesco Maraglino Department of Health Prevention, Ministry of Health, Rome Malgorzata Mikulska Division of Infectious Diseases, San Martino Hospital, University of Genoa, Genoa Cristina Mussini Division of Infectious Diseases, University Hospital of Modena, Modena Laura Pagani Department of Morphological, Imaging and Clinical Sciences, Microbiology Section, University of Pavia, Pavia Annalisa Pantosti Department of Infectious, Parasitic and Immune-Mediated Disease, Superior Healthcare Institute, Rome Saverio Parisi Division of Molecular Medicine, University of Padua, Padua Nicola Petrosillo National Institute of Infectious Diseases, INMI L. Spallanzani, Rome Marco Rizzi Division of Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo Bhanu Sinha Department of Medical Microbiology and Infection Control, University Medical Center Groningen, Netherlands Stefania Stefani Department of Bio-Medical Sciences-Laboratory of Molecular Medical Microbiology and Antibiotic-Resistance, University of Catania, Catania Evelina Tacconelli Division of Infectious Diseases, Department of Internal Medicine, Tubingen University Hospital, Tubingen, Germany Carlo Tascini Division of Infectious Diseases, "Monaldi-Cotugno-CTO" Hospital, Naples Marco Tinelli Division of Infectious and Tropical Diseases, Hospital of Lodi, Lodi Mario Tumbarello Dipartment of Infectious Diseases Sacro Cuore Catholic University, Division of Infectious Diseases A. Gemelli University Hospital, Rome Mario Venditti Department of Infectious Diseases, "La Sapienza" University Hospital of Rome, Rome Pierluigi Viale Division of Infectious Diseases, Department of Internal Medicine, Geriatrics and Nephrologic Diseases, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna Paolo Viganò Division of Infectious Diseases, Hospital of Legnano, Legnano Claudio Viscoli Division of Infectious Diseases, San Martino Hospital, University of Genoa, Genoa 5

6Thursday, March 9 AUDITORIUM ORLANDO ROOM Registration of Participants 07.45-08.45 Opening remarks 08.45-09.00 Message from the President of the Congress Keynote lecture Chairperson: A. Endimiani Can We really Apply "Precision Medicine" to Infectious Diseases? R. Bonomo 09.00-09.30 Session 1 Present and Future in Diagnostic of Bacterial Infections Moderatori: L. Pagani, F. Luzzaro, P. Grossi The impact of microbiota on human health and in infectious disease P.D. Cotter 09.30-10.00 From phenotypic to genotypic antibiotic stewardship in microbiological diagnostic: state of the art T. Giani 10.00-10.30 Epidemiology of multi drug resistance microrganisms in Italy A. Pantosti 10.30-11.00 Discussion 11.00-11.15

Session 2 Strategies to prevent the risks of infections in hospital and community Chairpersons: A. Chirianni, B. Cacopardo, F. Castelli The Italian programme to takle antibiotic resistance F. Maraglino 11.15-11.45 Strategies to prevent the risks of infections in LTCFs and geriatric settings G. Gavazzi 11.45-12.15 New models to improve antibiotic surgical prophylaxis N. Petrosillo 12.15-12.45 Discussion 12.45-13.00 Lunch 13.15-14.30 Session 3 Approaches to individualized antibiotic therapy in the era of multidrug resistance microrganisms Chairpersons: G. Magnani, S. Esposito Drug level monitoring for guiding antibiotic and antimicotic individualized treatment D. Cattaneo 14.30-15.00 Individualized antibiotic therapy of invasive infections due to multidrug-resistant gram negative bacteria M. Tumbarello 15.00-15.30 Treatment and outcome of MRSA bacteraemia M. Venditti 15.30-16.00 7

8Thursday, March 9 ORLANDO ROOM First experiences with new beta-lactam/ beta-lactamase inhibitor combinations, cephalosporin, oxazolidinones and glycopeptides M. Bassetti 16.00-16.30 Discussion 16.30-16.45 Session 4 Oral Communications Chairpersons: A. Davì, M. Rizzi, A.Franco CO1 Molecular analysis of KPC-producing escherichia coli clinical isolates emerged in 2016 in a hospital of Northern Italy C. Mauri (Lecco) 16.45-17.00 CO2 Epidemiological, clinical features and prognostic factors of pyogenic spondylodiscitis: a study in 160 patients with 2 years follow-up F. Taccari (Roma) 17.00-17.15 CO3 Evaluation of peripheral blood cultures taken in the emergency department for the diagnosis of invasive pneumococcal disease A. Anesi (Lodi) 17.15-17.30 CO4 Preliminary results from a carbapenemresistant enterobacteriaceae surveillance from invasive infections in Italy in 2016 G. Errico (Roma) 17.30-17.45 CO5 Clinical features and risk factors for mortality among patients with staphylococcus aureus bloodstream infections P. Brugnaro (Venezia) 17.45-18.00 CO6 Clinical, diagnostic and therapeutic aspects of implantable cardiac electronic device infections. A five-year retrospective analysis and comparison with literature M. Maritati (Ferrara) 18.00-18.15

CO7 Surveillance and control of infections by enterobacteria resistant to carbapenems (CRE) in a nursing-home R. D Angelo (Milano) 18.15-18.30 CO8 Enterococcus faecalis recurrent aortic prosthetic valve endocartisis G. Gattuso (Mantova) 18.30-18.45 SALA COLUCCI DELLE ROOM COLONNE Session 5 Update on HCV and HIV infections Chairpersons: A. D Arminio Monforte, P. Viganò Present and future for HIV care M. Galli 16.45-17.15 Prevalence, genotype distribution, and risk factors for hepatitis C infection among HIV co-infected patients C. Mussini 17.15-17.45 HCV and HBV therapy in 2017: current status G.B. Gaeta 17.45-18.15 Discussion 18.15-18.45 9

Friday, March 10 AUDITORIUM ORLANDO ROOM Keynote Lecture Chairperson: M. Tinelli Present and future of Infectious Diseases E. Tacconelli 09.00-09.30 Session 6 Antimicrobial stewardship Chairpersons: M. Andreoni, A. Cascio, S. Iannazzo The guidelines for antimicrobial prescription for an individualized treatment in hospital and community settings: opportunities or dangers? E. Concia 09.30-10.00 How to organize antimicrobial stewardship in hospital settings P. Viale 10.00-10.30 Bundle of an integrated antimicrobial stewardship program: clinical and financial evaluation B. Sinha 10.30-11.00 10 Session 7 Challenging complex infections Chairpersons: C. Contini, C. Viscoli Management of fungal infections in onco-haematological patients M. Mikulska 11.00-11.30 New sepsis definitions and treatment models T. Calandra 11.30-12.00 Antimicrobial treatment in the elderly M. Tinelli 12.00-12.30 Pathogenesis and treatment of orthopaedic biofilm infections S. Borrè 12.30-13.00 Discussion 13.00-13.15 Lunch 13.15-14.30

Session 8 Update on diagnosis and antimicrobial treatment in high risk for infection health-care settings Chairpersons: S. Parisi, C. Iacobello Diagnosis and treatment of C. difficile: state of the art E.J. Kuijper 14.30-15.00 Decolonization strategies for MDR bacteria: present and future perspectives C. Tascini 15.00-15.30 The pathogenetic role of toxins in skin and soft tissue infections S. Stefani 15.30-16.00 Management of pneumonia in health care and community settings M. Falcone 16.00-16.30 Mycobacteria in migrants population: testing, follow-up and treatment F. Franzetti 16.30-17.00 Discussion 17.00-17.15 Conclusion and CME questionary compilation 11

Poster Participants that would like to send abstracts are kindly invited to use only the dedicated online form available on the website and send it within February 13th 2017. Each participants has to be registered and can send a maximum of 2 abstracts. The Scientific Secretariat will send by email the confirmation within February 23rd 2017. There will be also a Poster Area and posters can be put up starting from March 9th at 08.00 and they will be exposed from March 9th to March 10th. Poster size: cm 70 width - cm 100 height Mounting materials will be available in the poster area. During poster presentation, the presence of at least one of the authors is mandatory. ORAL COMMUNICATION The Organizing Secretariat will communicate the confirmation of acceptance at the first author on the abstract form, together with date and time of the presentation. The duration of each oral communication will be 12 minutes, plus 3 minutes of discussion. ABSTRACT PRESENTATION DETAILS Abstracts must be written in English, with the following order: - Title: brief and written in capital letters - Author: initial of the given name following by the last name, no academic titles. Kindly underline the name of the authors who will make the presentation - Affiliation Use Word program, Times New Roman character, size 12 and single line spacing Maximum length: 1 page CONTENT Abstract must contain: Objectives of the studies Methods used Results and conclusions Eventual bibliographical quotes must be indicated in the text. Charts and diagrams can be used as long as they are included in the text page. 12

CME PROVIDER Nº 265 Nadirex International S.r.l. CME CREDITS The request for CME credits has been submitted to the Italian Ministry of Health: ID Nr. 265-178419 - CME credits: 12 - Physician - Biologist - Pharmacist. CME CREDITS FOR SPEAKERS (Italian Physicians) Speakers are entitled to one CME credits for every 30 consecutive minutes of teaching, independently of the credits attributed for the educational event. Chairpersons and Speakers are not entitled to CME credits as participants at events in which they carry out teaching activities. CME CERTIFICATE In order to obtain CME credits, participants must: - Attend 100% of the sessions indicated in the programme - Fill in the personal data form, the form evaluating the event, and the learning questionnaire and give them to the Organizational Secretariat at the end of the Congress. The CME certificate will be sent by mail after the Congress to the address given on the personal data form. CERTIFICATE OF ATTENDANCE A Certificate of Attendance will be given personally to all registered participants at the Organizing Secretariat s Desk at the end of the Congress. CONGRESS WORK All speakers must comply scrupulously with the times allocated to ensure the good outcome of the various sessions. The duration of each presentation will be communicated directly to the authors. CONGRESS DOCUMENTS AND BADGE The congress documents should be collected on-site at the registration desk. Name badges must be worn at all time during the Congress and in the exhibition area. TECHNICAL AND SCIENTIFIC EXHIBITION During the Congress, areas reserved for meetings between Congress participants and pharmaceutical companies will be available. There will not be display stands. OFFICIAL LANGUAGES Official languages of the Congress: Italian and English. Simultaneous translation will not be provided. General informations 13

Registration REGISTRATION FEES 244,00 ( 200,00 + 44,00 22% VAT) This registration fee includes: Participation at congress work Congress kit Educational material Certificate of Attendance CME certificate Coffee station and working lunches, as in the program A coffee station will be available at the Auditorium entrance during the Meeting REGISTRATION INSTRUCTIONS The registration form has to be filled in and sent to the Organizing Secretariat, together with the copy of the payment, within February 19th. Registration can be made: Online on the website www.congresso-amit.it By Email: info@nadirex.com By Fax: 0382/525736 By mail: sending to Nadirex International Via Riviera 39-27100 Pavia REQUEST FOR EXEMPTIONS FROM VAT (ART. 10 PARAGRAPH 20 D.P.R. 637/72) Public institutions requesting exemption from VAT on the payment of registration fees for their staff must tick the appropriate space on the registration form and stamp it with their official stamp mark. Requests without an institutional stamp mark cannot be accepted. It is not possible to ask for a reimbursement of VAT and relative accreditation notes once payment has been made. for administrative reasons, registration forms accompanied by errors in registration fees or without the required information will not be validated. 14 METHODS OF PAYMENT Bank transfer: NADIREX INTERNATIONAL S.r.l. IBAN IT73B0504811323000000030112 The copy of the bank transfer must be sent together with the registration form Credit Card: Visa, MasterCard, American Express Kindly fill the registration form with all the requested credit card details. Registrations without payment will not be accepted. CANCELLATIONS The Secretariat must be informed in writing of any cancellations. 80% of the amount paid will be refunded for cancellations made before January 14. No money will be refunded after that date.

Congress Venue Palazzo Castiglioni Corso Venezia, 47 20121 Milano - Italia From Central Station: - Metro 3 (Yellow line): direction San Donato, stop in Duomo station and take the Metro 1 (Red Line), direction Sesto F.S. and stop at Palestro Station. - Metro 2 (Green line): direction Cologno Nord/Gessate, stop at Loreto take the Metro 1 (Red Line), direction Bisceglie/Rho Fiera and stop at Palestro Station From Cadorna Station - Bus 94 and stop at Via Senato/Via Statuto walk along Corso Venezia for approx. 200 metres - Metro 1 (Red Line), direction Sesto F.S. and stop at Palestro Station From Porta Garibaldi Station - Metro 2 (Green line): direction Cologno Nord/Gessate, stop at Loreto take the Metro 1 (Red Line), direction Bisceglie/Rho Fiera and stop at Palestro Station From Lambrate Station: - Metro 2 (Green line): direction Assago Milanofiori Forum/Abbiategrasso, stop at Loreto take the Metro 1 (Red Line), direction Bisceglie/Rho Fiera and stop at Palestro Station From Rogoredo Station: - Metro 3 (Yellow line): direction Comasina, stop in Duomo station and take the Metro 1 (Red Line), direction Sesto F.S. and stop at Palestro Station From Porta Genova Station - Metro 2 (Green line): direction Cologno Nord/Gessate, stop at Cadorna Station and take the Metro 1 (Red Line), direction Sesto F.S. and stop at Palestro Station From Porta Venezia Station: - Metro 1 (Red Line), direction Bisceglie/Rho Fiera and stop at Palestro Station From Linate Airport - Bus 73 stop at San Babila/Corso Europa and take the Metro 1 (Red Line), direction Sesto F.S. and stop at Palestro Station From Malpensa Airport - Malpensa Express Train until Milano Cadorna Station, than take Metro 1 (Red Line), direction Sesto F.S. and stop at Palestro Station How to get there 15

Under the patronage of Ministry of Health ISS - Italian Health Superior Institute SIMIT - Italian Society of Infectious and Tropical Diseases ESCMID - European Society of Microbiology and Infectious Diseases AMCLI - Italian Association of Clinical Microbiologists SIV-ISV - Italian Society for Virology With the educational support of PLATINUM SPONSOR BASILEA PHARMACEUTICA GILEAD SCIENCES SRL MSD ITALIA SRL VIIV HEALTHCARE SRL ViiV Healthcare S.r.l. è sponsor commerciale parziale del presente Evento; il presente Evento è soggetto a deposito AIFA ai sensi e per gli effetti di cui all art. 124 del D.Lgs. 219/06. GOLDEN SPONSOR PFIZER ITALIA SRL ANGELINI ACRAF SPA ABBVIE SRL SILVER SPONSOR ASTELLAS PHARMA SPA BRISTOL MYERS SQUIBB SRL JANSSEN-CILAG SPA BIOMERIEUX ITALIA SPA NORDIC PHARMA SRL